Last updated: February 16, 2026
Overview
NDC 60505-4033 is marketed as a biosimilar to Herceptin (trastuzumab). Biosimilars targeting HER2-positive breast cancer are gaining market share due to patent expirations of brand-name biologics, leading to increased competition and downward pressure on prices.
Product Status and Market Dynamics
- Type: Biosimilar trastuzumab
- Approval: Approved by the FDA in 2019 for metastatic breast cancer and early-stage HER2-positive breast cancer [1].
- Market Entry: Since 2019, multiple biosimilars have entered the US market, bolstering competition.
- Market Share: Biosimilars collectively hold approximately 50-60% of trastuzumab sales since 2021 [2].
- Key Competitors: Mylan’s (now Viatris) Herzuma, Pfizer’s 抑, and others.
Pricing Trends
- Initial Launch Price: Biosimilars typically launch at 15-30% lower than the reference biologic. Herceptin’s average wholesale price (AWP) was approximately $3,300 per 440 mg dose in 2022 [3].
- Current Biosimilar Prices: Range from $2,200 to $2,800 per 440 mg dose, reflecting price erosion post-market entry.
- Volume-Based Discounts: Hospitals and insurers negotiate substantial discounts, reducing expenditure further.
Market Projections
- Market Size: US trastuzumab sales were around $1 billion annually in 2022 [4]. Assuming biosimilar penetration reaches approximately 70% by 2025, biosimilar sales could reach $700 million.
- Price Stability: Biosimilar prices are anticipated to decline by 10-20% annually over the next three years due to increased competition and manufacturing efficiencies.
- Total Market Value (2025): Estimated biosimilar trastuzumab market could be valued at approximately $560-630 million.
- Pricing Projection (2025): The average biosimilar dose may fall to $1,800 to $2,200 per 440 mg, with potential for further reductions depending on payer negotiations.
Regulatory and Policy Factors
- Payment Policies: CMS encourages biosimilar substitution under Medicare Part B, favoring lower-cost options.
- Intellectual Property: Patent challenges for Herceptin expired in 2019, enabling biosimilar entry.
- State Legislation: Some states restrict biosimilar substitution unless explicitly permitted, affecting market penetration.
Impacts on Stakeholders
- Manufacturers: Biosimilar producers benefit from increased market share and volume but face pricing pressures.
- Providers: Gain access to lower-cost alternatives with comparable efficacy, influencing treatment decisions.
- Payers: Achieve significant cost savings; incentives favor biosimilar adoption.
- Patients: Benefit from broader access to effective therapies at reduced out-of-pocket costs.
Key Takeaways
- NDC 60505-4033 is a biosimilar trastuzumab, entering a competitive market with rapid price erosion.
- Price projections suggest a decline to $1,800–$2,200 per 440 mg dose by 2025.
- Total market size is expected to be around $560-630 million, driven by increased biosimilar penetration.
- Policy shifts favor biosimilar adoption, further influencing pricing and market dynamics.
FAQs
1. What is the current market share of NDC 60505-4033?
It holds a relatively small share among trastuzumab biosimilars, with overall biosimilar HER2-positive therapies capturing roughly 50-60% of the market share.
2. How do biosimilar prices compare to the reference Herceptin?
Biosimilars generally price 15-30% lower, with current average wholesale prices around $2,200 to $2,800 per 440 mg dose versus Herceptin’s $3,300.
3. Will prices continue to decline?
Yes. Price erosion of 10-20% annually is expected in the biosimilar space over the next three years.
4. How do regulatory policies impact biosimilar pricing?
Policies favoring biosimilar substitution and Medicare reimbursement incentives promote price competition and lower retail prices.
5. What are the main factors influencing future market growth?
Patent expirations, manufacturer capacity, payer acceptance, and evolving clinical guidelines for HER2-positive breast cancer.
Sources
[1] FDA. (2019). Herceptin biosimilar approval.
[2] IQVIA. (2022). Biosimilar Market Trends.
[3] Red Book. (2022). Wholesale Acquisition Cost Data.
[4] EvaluatePharma. (2022). Oncology Market Report.
